Name: RALLYBIO CORP (RLYB) Stock
Brand: RALLYBIO CORP
Rating: 6 (3 reviews)

RLYB Latest News, Press Relases and Analysis

All

Press Releases

6 days ago - By: Chartmill

RALLYBIO CORP (NASDAQ:RLYB) Reports Q3 2025 Earnings Beat Fueled by Asset Sale and Advances Clinical Pipeline

6 days ago - By: Rallybio Corporation

Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates

20 days ago - By: Benzinga - Mentions: NBY CYH PMI INBX ...

12 Health Care Stocks Moving In Thursday's After-Market Session

a month ago - By: Benzinga - Mentions: ENTA ACHV GNPX KZR ...

12 Health Care Stocks Moving In Thursday's After-Market Session

2 months ago - By: Rallybio Corporation

Rallybio Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study

2 months ago - By: Rallybio Corporation

Rallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 Program

3 months ago - By: Yahoo Finance - Mentions: RXRX

Recursion Pharmaceuticals (RXRX) Expands AI Drug Discovery Pipeline with New Clinical Candid

3 months ago - By: Rallybio Corporation

Rallybio Reports Second Quarter 2025 Financial Results and Provides Business Updates

4 months ago - By: Yahoo Finance - Mentions: RXRX UBS GMAB

Recursion Pharmaceuticals (RXRX) Rallies 8.7% on Hypophosphatasia

4 months ago - By: Yahoo Finance - Mentions: RXRX

Rallybio to sell interest in REV102 to Recursion Pharmaceuticals for up to $25M

4 months ago - By: Yahoo Finance - Mentions: RXRX

Here's Why Shares in Recursion Pharmaceuticals Surged Today

4 months ago - By: The Motley Fool - Mentions: RXRX

Here's Why Shares in Recursion Pharmaceuticals Surged Today

4 months ago - By: Rallybio Corporation

Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals

5 months ago - By: Rallybio Corporation

Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study

6 months ago - By: Rallybio Corporation

Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates

7 months ago - By: Rallybio Corporation

Rallybio to Present at the 2025 Citizens JMP Life Sciences Conference

7 months ago - By: Yahoo Finance - Mentions: CALM

Trade policy changes alone won’t bring manufacturing back

7 months ago - By: Rallybio Corporation

Rallybio to Discontinue Development of RLYB212 for Prevention of FNAIT

8 months ago - By: Rallybio Corporation

Rallybio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

9 months ago - By: Rallybio Corporation

Rallybio to Present at the TD Cowen 45th Annual Health Care Conference

9 months ago - By: Rallybio Corporation

RALLYBIO CORP (RLYB) Stock News

RLYB Latest News, Press Relases and Analysis

RALLYBIO CORP (NASDAQ:RLYB) Reports Q3 2025 Earnings Beat Fueled by Asset Sale and Advances Clinical Pipeline

Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates

12 Health Care Stocks Moving In Thursday's After-Market Session

12 Health Care Stocks Moving In Thursday's After-Market Session

Rallybio Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study

Rallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 Program

Recursion Pharmaceuticals (RXRX) Expands AI Drug Discovery Pipeline with New Clinical Candid

Rallybio Reports Second Quarter 2025 Financial Results and Provides Business Updates

Recursion Pharmaceuticals (RXRX) Rallies 8.7% on Hypophosphatasia

Rallybio to sell interest in REV102 to Recursion Pharmaceuticals for up to $25M

Here's Why Shares in Recursion Pharmaceuticals Surged Today

Here's Why Shares in Recursion Pharmaceuticals Surged Today

Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals

Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study

Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates

Rallybio to Present at the 2025 Citizens JMP Life Sciences Conference

Trade policy changes alone won’t bring manufacturing back

Rallybio to Discontinue Development of RLYB212 for Prevention of FNAIT

Rallybio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Rallybio to Present at the TD Cowen 45th Annual Health Care Conference

Rallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial